Our Latest News - BUHLMANN

A New Rapid Test for Fecal Calprotectin Predicts Endoscopic Remission and Postoperative Recurrence in Crohn’s Disease.

Quantum Blue® fCAL Citation Lobatón, T, , López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's & colitis. J Crohns Colitis. 2013 Dec; 7(12):e641-51. doi: 10.1016/j.crohns.2013.05.005. Highlight from this Publication “FC determined by rapid quantitative test

Validation of a Point-of-Care Desk Top Device to Quantitate Fecal Calprotectin and Distinguish Inflammatory Bowel Disease from Irritable Bowel Syndrome

Quantum Blue® fCAL Citation Sydora, M. J., Sydora BC, Fedorak RN, 2012, Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome, J Crohns Colitis. 2012 Mar;6(2):207-14. doi: 10.1016/j.crohns.2011.08.008. Highlight from this Publication “Quantum Blue Reader® calprotectin levels were available within 30 min and correlated

Value Fecal Calprotectin in the Evaluation of Patients with Abdominal Discomfort: An Observational Study

BÜHLMANN fCAL® ELISA Citation Manz, M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012 Jan 10;12:5. doi: 10.1186/1471-230X-12-5. Highlights from this Publication “All together, those results support the concept that fecal calprotectin is

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47. doi: 10.1016/j.cca.2012.11.008 Highlights from this Publication “…we demonstrated, that the

Comparison of Six Different Calprotectin Assays for the Assessment of Inflammatory Bowel Disease

Quantum Blue® fCAL Citation Labaere, D, Smismans A, Olmen A, Christiaens P, D’Haens G, Moons V, Cuyle P, Frans J, and Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease, United European Gastroenterology J. 2014 Feb; 2(1): 30–37. doi: 10.1177/2050640613518201 Highlight from this Publication "The EliA [Phadia] cut off for diagnosis was optimal at a level of 15 mg/g. This

Fecal Calprotectin: Towards a Standardized Use for Inflammatory Bowel Disease Management in Routine Practice

Value of Fecal Calprotectin in the Diagnosis of IBD: Edouard, Louis. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. Journal of Crohn's and Colitis, 2015, 1–3 doi:10.1093/ecco-jcc/jju012. “…fecal calprotectin as a unique first line test would be sufficient to decide in which patient to perform further endoscopic or medical imaging

Flow CAST® eBook- Kinase Inhibition Assay for BTK, SYK, and PI3K Activity

Flow CAST® eBook Testing Potency and Efficacy of Inhibitors of PI3K, PI3K, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several

A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis

Quantum Blue® fCAL Citation Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013 Apr;19(5):1034-42. doi: 10.1097/MIB.0b013e3182802b6e. PMID: 23470502 Highlight from this Publication “FC determined by QPOCT was an accurate surrogate marker of “endoscopic remission”

Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to

Visit BUHLMANN Diagnostics Corp at AACC 2016

When: July 31 - August 4, 2016 Where: Philadelphia, PA Booth: #4202 Learn More: AACC 2016

BUHLMANN News

A New Rapid Test for Fecal Calprotectin Predicts Endoscopic Remission and Postoperative Recurrence in Crohn’s Disease.

Validation of a Point-of-Care Desk Top Device to Quantitate Fecal Calprotectin and Distinguish Inflammatory Bowel Disease from Irritable Bowel Syndrome

Value Fecal Calprotectin in the Evaluation of Patients with Abdominal Discomfort: An Observational Study

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

Comparison of Six Different Calprotectin Assays for the Assessment of Inflammatory Bowel Disease

Fecal Calprotectin: Towards a Standardized Use for Inflammatory Bowel Disease Management in Routine Practice

Flow CAST® eBook- Kinase Inhibition Assay for BTK, SYK, and PI3K Activity

A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis

Other BÜHLMANN Fecal Calprotectin Assays Citations

Visit BUHLMANN Diagnostics Corp at AACC 2016

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US